Publications by authors named "Barry Singer"

Claim this Profile
L
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.
Tjalf Ziemssen, Ann D Bass, Bart Van Wijmeersch, Sara Eichau, Stephan Richter, Barry A Singer

Ther Adv Neurol Disord· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis.
Barry A Singer, Dawn Morgan, Julie A Stamm, Anita A Williams

Neurol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
Krzysztof Selmaj, Karsten Roth, Josef Höfler, Klaus Vitzithum, Rafał Derlacz, Barry Singer

BioDrugs· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen

Neurol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
Barry A Singer, Jenny Feng, Horacio Chiong-Rivero

J Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn

Neurol Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold

Mult Scler· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Alasdair J Coles, Anat Achiron, Anthony Traboulsee, Barry A Singer, Carlo Pozzilli

Ther Adv Neurol Disord· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Tjalf Ziemssen, Virender Bhan, Jeremy Chataway, Tanuja Chitnis, Bruce Anthony Campbell Cree, Barry Singer

Neurol Neuroimmunol Neuroinflamm· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.
Yang Mao-Draayer, Jeffrey A Cohen, Amit Bar-Or, May H Han, Barry Singer

Mult Scler J Exp Transl Clin· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Gavin Giovannoni, Barry A Singer, Delphine Issard, Dominic Jack, Patrick Vermersch

Mult Scler· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
Mark Gudesblatt, Cortnee Roman, Barry A Singer, Hollie Schmidt, Jessica Thomas

Adv Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L Arnold, Jelena Drulovic, Barry A Singer

Adv Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping.
Barry A Singer, Shannon Keith, Amy Howerter, Helen Doll, Timothy Pham

Patient Prefer Adherence· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
Annette Wundes, Sibyl Wray, Ralf Gold, Barry A Singer, Elzbieta Jasinska

Ther Adv Neurol Disord· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich, Barry A Singer

Mult Scler· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
Antonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, Giancarlo Comi, Eva Kubala Havrdova, Barry A Singer

Neurol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Bart Van Wijmeersch, Barry A Singer, Aaron Boster, Simon Broadley, Óscar Fernández

Mult Scler· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Tjalf Ziemssen, Ann D Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau, Barry A Singer

CNS Drugs· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Bruce A C Cree, Myla D Goldman, John R Corboy, Barry A Singer, Edward J Fox

JAMA Neurol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Mark S Freedman, Staley Brod, Barry A Singer, Bruce A Cohen, Brooke Hayward

J Neurol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Ann D Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Mäurer, Aaron Boster, Barry Singer

Int J MS Care· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.
Edward J Fox, Guy J Buckle, Barry Singer, Vibhuti Singh, Aaron Boster

Neurol Clin Pract· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod.
Jeffrey A Cohen, Amit Bar-Or, Bruce A C Cree, Yang Mao-Draayer, May H Han, Barry Singer

Mult Scler J Exp Transl Clin· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
Sibyl Wray, Brooke Hayward, Fernando Dangond, Barry Singer

Expert Opin Drug Deliv· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis